methyl N,N-bis(methoxycarbonyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N,N-bis(methoxycarbonyl)carbamate
• 化学式: C₆H₉NO₆
• 分子量: 191.14
• InChiKey: MUXXZMZLBZSROQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] BIOTINIDASE RESISTANT BIOTINYL COMPOUNDS<br/>[FR] COMPOSÉS DE BIOTINYLE RÉSISTANT À LA BIOTINIDASE
  申请人：UNIV EDINBURGH

  公开号：WO2013144604A1

  公开（公告）日：2013-10-03

  Disclosed are biotinidase resistant biotinyl-conjugates, and uses thereof. The conjugates comprise a biotinyl moiety coupled to a therapeutic or diagnostic moiety by a triazole group. The conjugates have applications as diagnostic or therapeutic agents, in methods of diagnosis or treatment of a subject, for example as MRI contrast agents in MRI imaging of a subject. In particular, biotinyl-chelate complexes find utility in two and three step pretargeting strategies and have high affinity for avidin, streptavidin and related proteins. Also disclosed are biotinylating agents and kits, and the use of compounds for biotinylation, including for the synthesis of biotinyl-chelate complexes and biotinyl-conjugates.

  本发明涉及耐生物素酶的生物素基共轭物及其用途。该共轭物包括通过三唑基团将生物素基团与治疗或诊断基团耦合而成。该共轭物可用于诊断或治疗剂，用于诊断或治疗主体的方法，例如用于主体的MRI成像中作为MRI对比剂。特别是，生物素基螯合物复合物在两步或三步预靶向策略中具有实用性，并具有高亲和力，可与亲合素、链霉亲合素和相关蛋白结合。本发明还涉及生物素化试剂和试剂盒，以及用于生物素化的化合物的使用，包括用于合成生物素基螯合物复合物和生物素基共轭物的化合物。
• Methods of treatment of HIV-associated conditions
  申请人：——

  公开号：US20020182272A1

  公开（公告）日：2002-12-05

  A method of treating an HIV-related condition includes a step in which a patient is diagnosed as being infected with an HIV virus and having an HIV related condition. In a further step, a composition that comprises at least one of a chelator and an antiviral agent is administered to the patient, wherein the antiviral agent comprises a plant extract or a synthetic or isolated compound from a plant that is demonstrated to have an antiviral effect.

  一种治疗艾滋病毒相关疾病的方法包括一个步骤，在该步骤中，患者被诊断为感染了艾滋病毒并患有艾滋病毒相关疾病。在进一步的步骤中，向患者施用包含螯合剂和抗病毒剂中至少一种的组合物，其中抗病毒剂包含植物提取物或从植物中合成或分离出的化合物，该植物提取物或化合物已被证明具有抗病毒作用。
• Time release reverse transcriptase inhibitors
  申请人：——

  公开号：US20020187957A1

  公开（公告）日：2002-12-12

  A pharmacological composition comprises a reverse transcriptase inhibitor in a quantity sufficient to reduce a viral serum titer of a virus in an amount of at least 20% over a period of at least 6 hours, wherein preferred reverse transcriptase inhibitor comprise a plant extract.

  一种药理组合物包含一种逆转录酶抑制剂，其数量足以在至少 6 小时内将病毒血清滴度降低至少 20%，其中优选的逆转录酶抑制剂包括一种植物提取物。
• Time release chelators
  申请人：——

  公开号：US20020182217A1

  公开（公告）日：2002-12-05

  A pharmacological composition comprises a chelator in a time release formulation in a quantity sufficient to reduce a serum concentration of a bivalent metal in an amount of at least 20% for a period of at least 8 hrs. Preferred chelators chelate at least one of Ca 2+ and Mg 2+ .

  一种药理组合物包含一种螯合剂，该螯合剂为定时释放制剂，其数量足以在至少 8 小时内将二价金属的血清浓度降低至少 20%。首选的螯合剂可螯合 Ca 2&plus； 和镁 2&plus； .
• Treatment of virus using chelator and antiviral agent
  申请人：——

  公开号：US20020182227A1

  公开（公告）日：2002-12-05

  A pharmacological composition comprises an antiviral agent and a chelator in a quantity sufficient to reduce a serum concentration of a bivalent metal in an amount of at least 25%, wherein preferred antiviral agents include protease inhibitors, reverse transcriptase inhibitors, and/or an antibody, and wherein preferred chelators chelate at least one of Ca 2+ and Mg 2+ .

  一种药理组合物由抗病毒剂和螯合剂组成，抗病毒剂和螯合剂的用量足以使血清中的二价金属浓度降低至少 25%，其中优选的抗病毒剂包括蛋白酶抑制剂、逆转录酶抑制剂和/或抗体，优选的螯合剂螯合 Ca 2&plus； 和镁 2&plus； .